Shionogi Renews 10-Year Goal After Infectious Disease Success

Push For Faster Xocova Growth

Shionogi renews its 10-year strategic plan originally announced in 2020 following the successful debut of COVID-19 therapeutic Xocova. Fulfilling its 2025 goals ahead of schedule, its new strategy focuses on HIV and COVID-19 and new product launches.

Shionogi moved its timing to leap earlier than expected before the pandemic.
Shionogi makes early transition to new growth plan • Source: Shutterstock

Shionogi & Co. Ltd. has announced the renewal of its mid-term 10-year strategy plan, this time covering the period to 2030.

Following the successful performance of infectious disease products, including its oral COVID-19 therapeutic Xocova (ensitrelvir) in Japan and the antibiotic...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip